Advantages and Challenges of Tailored Regimens for Drug-Resistant Tuberculosis: A StopTB Italia Look into the Future

References

• World Health Organization. Documentation for World Health Assembly 67 (A67/11).Geneva: World Health Organization; 2014.
   Google Scholar
• World Health Organization. Global tuberculosis report 2019. (WHO/CDS/TB/2019.15).Geneva: World Health Organization; 2019.
   Google Scholar
• Riccardi N, Alagna R, Saderi L, et al., for StopTB Italia Onlus Group. Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres. BMC Infect Dis. 2019;19(1):564. doi:10.1186/s12879-019-4211-031253115
   PubMed Web of Science ®Google Scholar
• Villa S, Ferrarese M, Sotgiu G, et al. Latent tuberculosis infection treatment completion while shifting prescription from isoniazid-only to rifampicin-containing regimens: a two-decade experience in Milan, Italy. J Clin Med. 2020;9(1):101. doi:10.3390/jcm9010101
   Web of Science ®Google Scholar
• Villa S, Codecasa LR, Faccini M, et al. Tuberculosis among asylum seekers in Milan, Italy: epidemiological analysis and evaluation of interventions. Eur Respir J. 2019;54(4):100896. doi:10.1183/13993003.00896-2019
   Web of Science ®Google Scholar
• Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2013;41(6):1393–1400. doi:10.1183/09031936.00125812,23018916
   PubMed Web of Science ®Google Scholar
• Pinto L, Menzies D. Treatment of drug-resistant tuberculosis. Infect Drug Resist. 2011;4:129–135. doi:10.2147/IDR.S1033221904458
   PubMedGoogle Scholar
• WHO consolidated guidelines on tuberculosis. Module 4: Treatment - Drug-Resistant Tuberculosis Treatment. Licence: CC BY-NC-SA 3.0 IGO Geneva: World Health Organization;2020.
   Google Scholar
• Wang MG, Huang WW, Wang Y, et al. Association between tobacco smoking and drug-resistant tuberculosis. Infect Drug Resist. 2018;11:873–887. doi:10.2147/IDR.S16459629928135
   PubMed Web of Science ®Google Scholar
• World Health Organization. Treatment of Tuberculosis: guidelines 4th edition. (WHO/HTM/TB/2009.420). Geneva: World Health Organization; 2010.
   Google Scholar
• Zumla A, Ippolito G, Ntoumi F, et al. Host-directed therapies and holistic care for tuberculosis. Lancet Respir Med. 2020;8(4):337–340. doi:10.1016/S2213-2600(20)30078-332113574
   PubMed Web of Science ®Google Scholar
• Alsultan A, Et Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74(8):839–854. doi:10.1007/s40265-014-0222-824846578
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Alffenaar JW, Centis R, et al. Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment. Int J Infect Dis. 2015;32:101–104. doi:10.1016/j.ijid.2014.12.00125809764
   PubMed Web of Science ®Google Scholar
• Byng-Maddick R, Et Noursadeghi M. Does tuberculosis threaten our ageing populations? BMC Infect Dis. 2016;16(1):119. doi:10.1186/s12879-016-1451-026968654
   PubMed Web of Science ®Google Scholar
• Alffenaar JC, Akkerman OW, Kim HY, Tiberi S, Migliori GB. Precision and personalized medicine and anti-TB treatment: is TDM feasible for programmatic use? Int J Infect Dis. 2020;92:S5–S9. doi:10.1016/j.ijid.2020.01.041
   Web of Science ®Google Scholar
• Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 2011;%1 di %266 Suppl 4:iv7–iv15. doi:10.1093/jac/dkr072
   Web of Science ®Google Scholar
• Pea F, Furlanut M, Cojutti P, et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother. 2010;54(11):4605–4610. doi:10.1128/AAC.00177-1020733043
   PubMed Web of Science ®Google Scholar
• van den Elsen SHJ, Oostenbrink LM, Heysell SK, et al. Systematic review of salivary versus blood concentrations of antituberculosis drugs and their potential for salivary therapeutic drug monitoring. Ther Drug Monit. 2018;40(1):17–37. doi:10.1097/FTD.000000000000046229120971
   PubMed Web of Science ®Google Scholar
• Mota L, Al-Efraij K, Campbell JR, Cook VJ, Marra F, Johnston J. Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2016;20(6):819–826. doi:10.5588/ijtld.15.080327155187
   PubMed Web of Science ®Google Scholar
• Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62(15):2169–2183. doi:10.2165/00003495-200262150-0000112381217
   PubMed Web of Science ®Google Scholar
• Heysell SK, Moore JL, Staley D, Dodge D, Houpt ER. Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA. Tuberc Res Treat. 2013;2013:129,723. doi:10.1155/2013/129723
   Google Scholar
• Ebers A, Stroup S, Mpagama S, et al. Determination of plasma concentrations of levofloxacin by high-performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania. PLoS One. 2017;12(1):e0170663. doi:10.1371/journal.pone.017066328141813
   PubMed Web of Science ®Google Scholar
• Naidoo A, Naidoo K, McIlleron H, Essack S, Padayatchi N. A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis. J Clin Pharmacol. 2017;57(11):1369–1386. doi:10.1002/jcph.96828741299
   PubMed Web of Science ®Google Scholar
• Davies Forsman L, Niward K, Hu Y, et al. Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study. BMJ Open. 2018;8(9):e023899. doi:10.1136/bmjopen-2018-023899
   Web of Science ®Google Scholar
• Pea F, Furlanut M, Cojutti P, et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother. 2010;54(11):4605–4610. doi:10.1128/AAC.00177-1020733043
   PubMed Web of Science ®Google Scholar
• Bolhuis MS, Tiberi S, Sotgiu G, et al. Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study. Eur Respir J. 2015;46(4):1205–1207. doi:10.1183/13993003.00606-201526160870
   PubMed Web of Science ®Google Scholar
• Schoenenberger-Arnaiz JA, Ahmad-Diaz F, Miralbes-Torner M, et al. Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients. European Journal of Hospital Pharmacy. 2020;27:e30–e35.
   Google Scholar
• Scharf C, Paal M, Schroeder I, et al. Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness-Experience and Recommendations from One Year in Routine Clinical Practice. Antibiotics (Basel). 2020;9(3):131. doi:10.3390/antibiotics9030131
   Web of Science ®Google Scholar
• Zhang M, Wang S, Wilffert B, et al. The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis. Br J Clin Pharmacol. 2018;84(12):2747–2760. doi:10.1111/bcp.1372230047605
   PubMed Web of Science ®Google Scholar
• Fava VM, Schurr E. Evaluating the impact of LTA4H genotype and immune status on survival from tuberculous meningitis. J Infect Dis. 2017;215(7):1011–1013. doi:10.1093/infdis/jix05228419367
   PubMed Web of Science ®Google Scholar
• Goldani LZ, Spessatto CO, Nunes DL, et al. Management of severe gastrointestinal tuberculosis with injectable antituberculous drugs. Trop Med Health. 2015;43(3):191–194. doi:10.2149/tmh.2015-0926543395
   PubMedGoogle Scholar
• Cherenko S, Lytvynenko N. Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis. Eur Respir J. 2013;42:P2814.
   Web of Science ®Google Scholar
• Chantaphakul H, Cheungpasitporn W, Ruxrungtham K, Klaewsongkram J. Adverse reaction to anti-tuberculosis drugs. J Allergy Clin Immunol. 2010;125(2):AB154. doi:10.1016/j.jaci.2009.12.604,
   Web of Science ®Google Scholar
• Cabibbe AM, Walker TM, Niemann S, Cirillo DM. Whole genome sequencing of Mycobacterium tuberculosis. Eur Respir J. 2018;52:1801163. doi:10.1183/13993003.01163-201830209198
   PubMed Web of Science ®Google Scholar
• de Steenwinkel JE, Ten Kate MT, de Knegt GJ, et al. Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB. Emerg Infect Dis. 2012;18:660–663. doi:10.3201/eid1804.11091222469099
   PubMed Web of Science ®Google Scholar
• Riccardi N, Giannini B, Borghesi ML, et al. Time to change the single-centre approach to management of patients with tuberculosis: a novel network. ERJ Open Res. 2018;%1 di %24(1):00108–2017. doi:10.1183/23120541.00108-2017
   Google Scholar
• Giannini B, Riccardi N, Cenderello G, Di Biagio A, Dentone C, Giacomini M. From liguria HIV web to liguria infectious diseases network: how a digital platform improved doctors’ work and patients’ care. AIDS Res Hum Retroviruses. 2018;34(3):239–240. doi:10.1089/aid.2017.006429466022
   PubMed Web of Science ®Google Scholar
• Elangovan R, Et Arulchelvan S. A study on the role of mobile phone communication in tuberculosis DOTS treatment. Indian J Community Med. 2013;38(4):229–233. doi:10.4103/0970-0218.12015824302824
   PubMedGoogle Scholar
• Riccardi N, Del Puente F, Magnè F, Taramasso L, Di Biagio A. Bedaquiline: a new hope for shorter and better anti-tuberculosis regimens. Recent Pat Antiinfect Drug Discov. 2018;13(1):3–11. doi:10.2174/1574891X1266617061910190428625141
   PubMedGoogle Scholar
• Rock J. Tuberculosis drug discovery in the CRISPR era. PLoS Pathog. 2019;15(9):e1007975. doi:10.1371/journal.ppat.100797531536613
   PubMed Web of Science ®Google Scholar
• Warner DF, Et Mizrahi V. Shortening treatment for tuberculosis - back to basics. N Engl J Med. 2014;371(17):1642–1643. doi:10.1056/NEJMe141097725337754
   PubMed Web of Science ®Google Scholar